Prevnar 20 (Apexxnar) Pneumococcal Vaccine — Vax-Before-Travel

Prevnar 20 (Apexxnar) Pneumococcal Vaccine

Fact checked by Robert Carlson, MD

May 24

5 min read

Pfizer Completes Third Phase Three 20vPnC Vaccine Study

PF-06482077 is a 20-Valent pneumococcal conjugate vaccine candidate (20vPnC) helping protect people from invasive pneumococcal disease and pneumonia

two people playing the guitar at sunset

Fact checked by Robert Carlson, MD

Mar 18

4 min read

Pneumococcal Conjugate Vaccine Candidate Expected to Meet Licensure Criteria

Adult 20vPnC vaccine candidate indicated for the majority of currently circulating pneumococcal disease

adult jogging on a lonely road

Fact checked by Robert Carlson, MD

Sep 9

3 min read

3-Doses of 20vPnC Vaccine Reported Safe For Infants

PF-06482077 vaccine candidate is for the prevention of invasive disease and otitis media caused by Streptococcus pneumoniae serotypes

older hand touching a baby's hand

Clinical Trials

Fact checked by Robert Carlson, MD

Apr 16

3 min read

20-Valent Pneumococcal Conjugate Vaccine Candidate Posts Positive Phase 2 Data

Pfizer’s PF-06482077 20vPnC vaccine candidate includes the 13 serotypes contained in Prevnar 13 vaccine

grandfather holding sleeping grand daughter

Fact checked by Robert Carlson, MD

Sep 20

3 min read

20-Valent Pneumococcal Conjugate Vaccine Candidate Eligible for FDA’s Fast Track Designation Program

Pfizer 20vPnC vaccine candidate PF-06482077 received FDA Breakthrough Therapy designation

older man walking on a sunny beach